170 related articles for article (PubMed ID: 18205559)
1. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
2. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
3. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
4. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
5. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Grocott R; Metcalfe S
N Z Med J; 2005 Oct; 118(1223):U1690. PubMed ID: 16224510
[TBL] [Abstract][Full Text] [Related]
6. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
Carter D; Vogan A; Haji Ali Afzali H
Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
[TBL] [Abstract][Full Text] [Related]
7. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
Wang S; Gum D; Merlin T
Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
[TBL] [Abstract][Full Text] [Related]
8. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
9. Priority-setting processes for medicines: the United Kingdom, Australia and New Zealand.
Manning J
J Law Med; 2011 Mar; 18(3):439-52. PubMed ID: 21528732
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
Henry D
Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
[TBL] [Abstract][Full Text] [Related]
11. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
Fischer KE; Heisser T; Stargardt T
Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
[TBL] [Abstract][Full Text] [Related]
12. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
13. Uptake of new medicines in New Zealand: evidence of a waiting list.
Barber JM; Sheehy KP
N Z Med J; 2015 Apr; 128(1412):10-20. PubMed ID: 25899488
[TBL] [Abstract][Full Text] [Related]
14. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
Morgan SG; McMahon M; Mitton C; Roughead E; Kirk R; Kanavos P; Menon D
Health Aff (Millwood); 2006; 25(2):337-47. PubMed ID: 16522575
[TBL] [Abstract][Full Text] [Related]
15. Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
Grocott R; Metcalfe S; Alexander P; Werner R
N Z Med J; 2013 Jul; 126(1378):60-73. PubMed ID: 24045316
[TBL] [Abstract][Full Text] [Related]
16. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
Harris AH; Hill SR; Chin G; Li JJ; Walkom E
Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
18. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
Trowman R; Chung H; Longson C; Littlejohns P; Clark P
Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
[TBL] [Abstract][Full Text] [Related]
19. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
[TBL] [Abstract][Full Text] [Related]
20. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
